Clinico-pathological Characteristics of P63 Expression in B-cell Lymphoma

Overview

Journal Cancer Sci

Specialty Oncology

Date 2006 Aug 22

PMID 16918993

Citations 20

Authors

Noriyasu Fukushima

Toshimi Satoh

Naoko Sueoka

Akemi Sato

Masaru Ide

Takashi Hisatomi

Nobuo Kuwahara

Rika Tomimasu

Naoko Tsuneyoshi

Noriko Funai

Masayuki Sano

Osamu Tokunaga

Eisaburo Sueoka

Affiliations

Soon will be listed here.

Abstract

A member of the family of p53-related genes, p63 plays a role in regulating epithelial proliferation and differentiation programs, but the pathological and clinical meaning of p63 in B-cell lymphoma has not been elucidated. We investigated the expression pattern of p63 in B-cell malignancies, and evaluated the correlation between the expression of p63 and other germinal center markers. Ninety-eight B-cell lymphomas (28 FCL, 5 MCL, and 65 DLBCL) were analyzed by immunohistochemical examination for p63, bcl-6, CD10 and MUM-1 proteins, and for rearrangement of bcl-2/IgH. Expression of p63 was observed in the nuclei of tumor cells obtained from 15 of 28 (54%) FCL, 22 of 65 (34%) DLBCL, but none of 5 MCL. In DLBCL, the expression of p63 and bcl-6 showed a significant correlation (P < 0.02), but no correlation was observed between p63 and expression of CD10, MUM-1, or bcl-2/IgH rearrangement. RT-PCR revealed that TAp63alpha-type transcripts, a possible negative regulator of transcriptional activation of p21 promoter, were major transcripts in B-cell lymphoma tissues. As for prognostic significance, only patients in the p63 positive group of FCL died, and in the non-germinal center group, the p63 positive cases appeared to have inferior overall survival than other groups in DLBCL. Our preliminary results suggested that p63 expression is a disadvantageous factor for prognosis in this subgroup of B-cell lymphomas.

Citing Articles

Multisystem ALK-positive histiocytosis: a multi-case study and literature review.

Liu W, Liu H, Wang W, Tang Y, Zhao S, Zhang W Orphanet J Rare Dis. 2023; 18(1):53.

PMID: 36915094 PMC: 10010018. DOI: 10.1186/s13023-023-02649-x.

Prognostic Significance of p53 and p63 in Diffuse Large B-Cell Lymphoma: A Single-Institution Experience.

Alvarez Moreno J, Bahmad H, Aljamal A, Delgado R, Salami A, Guillot C Curr Oncol. 2023; 30(2):1314-1331.

PMID: 36826063 PMC: 9955855. DOI: 10.3390/curroncol30020102.

ΔNp63α promotes Epstein-Barr virus latency in undifferentiated epithelial cells.

Van Sciver N, Ohashi M, Nawandar D, Pauly N, Lee D, Makielski K PLoS Pathog. 2021; 17(11):e1010045.

PMID: 34748616 PMC: 8601603. DOI: 10.1371/journal.ppat.1010045.

ALK-Negative Anaplastic Large Cell Lymphoma: Current Concepts and Molecular Pathogenesis of a Heterogeneous Group of Large T-Cell Lymphomas.

Pina-Oviedo S, Ortiz-Hidalgo C, Carballo-Zarate A, Zarate-Osorno A Cancers (Basel). 2021; 13(18).

PMID: 34572893 PMC: 8472588. DOI: 10.3390/cancers13184667.

TCL1A, B Cell Regulation and Tolerance in Renal Transplantation.

Brinas F, Danger R, Brouard S Cells. 2021; 10(6).

PMID: 34206047 PMC: 8230170. DOI: 10.3390/cells10061367.

References

Colomo L, Lopez-Guillermo A, Perales M, Rives S, Martinez A, Bosch F . Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood. 2002; 101(1):78-84. DOI: 10.1182/blood-2002-04-1286. View

Rosenwald A, Wright G, Chan W, Connors J, Campo E, Fisher R . The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002; 346(25):1937-47. DOI: 10.1056/NEJMoa012914. View

Pasqualucci L, Bereshchenko O, Bereschenko O, Niu H, Klein U, Basso K . Molecular pathogenesis of non-Hodgkin's lymphoma: the role of Bcl-6. Leuk Lymphoma. 2004; 44 Suppl 3:S5-12. DOI: 10.1080/10428190310001621588. View

Zigeuner R, Tsybrovskyy O, Ratschek M, Rehak P, Lipsky K, Langner C . Prognostic impact of p63 and p53 expression in upper urinary tract transitional cell carcinoma. Urology. 2004; 63(6):1079-83. DOI: 10.1016/j.urology.2004.01.009. View

Solal-Celigny P, Roy P, Colombat P, White J, Armitage J, Arranz-Saez R . Follicular lymphoma international prognostic index. Blood. 2004; 104(5):1258-65. DOI: 10.1182/blood-2003-12-4434. View

Mirza I, MacPHERSON N, Paproski S, Gascoyne R, Yang B, Finn W . Primary cutaneous follicular lymphoma: an assessment of clinical, histopathologic, immunophenotypic, and molecular features. J Clin Oncol. 2002; 20(3):647-55. DOI: 10.1200/JCO.2002.20.3.647. View

Massion P, Taflan P, Rahman S, Yildiz P, Shyr Y, Edgerton M . Significance of p63 amplification and overexpression in lung cancer development and prognosis. Cancer Res. 2003; 63(21):7113-21. View

Marin M, Kaelin Jr W . p63 and p73: old members of a new family. Biochim Biophys Acta. 2000; 1470(3):M93-M100. DOI: 10.1016/s0304-419x(00)00010-x. View

Montoto S, Lopez-Guillermo A, Colomer D, Esteve J, Bosch F, Ferrer A . Incidence and clinical significance of bcl-2/IgH rearrangements in follicular lymphoma. Leuk Lymphoma. 2003; 44(1):71-6. DOI: 10.1080/1042819021000050052. View

10.

Yang A, Schweitzer R, Sun D, Kaghad M, Walker N, Bronson R . p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature. 1999; 398(6729):714-8. DOI: 10.1038/19539. View

11.

Hedvat C, Teruya-Feldstein J, Puig P, Capodieci P, Dudas M, Pica N . Expression of p63 in diffuse large B-cell lymphoma. Appl Immunohistochem Mol Morphol. 2005; 13(3):237-42. DOI: 10.1097/01.pai.0000142160.52670.ce. View

12.

Levrero M, De Laurenzi V, Costanzo A, Gong J, Wang J, Melino G . The p53/p63/p73 family of transcription factors: overlapping and distinct functions. J Cell Sci. 2000; 113 ( Pt 10):1661-70. DOI: 10.1242/jcs.113.10.1661. View

13.

Lopez-Guillermo A, Cabanillas F, McDonnell T, McLaughlin P, Smith T, Pugh W . Correlation of bcl-2 rearrangement with clinical characteristics and outcome in indolent follicular lymphoma. Blood. 1999; 93(9):3081-7. View

14.

Natkunam Y, Warnke R, Montgomery K, Falini B, van de Rijn M . Analysis of MUM1/IRF4 protein expression using tissue microarrays and immunohistochemistry. Mod Pathol. 2001; 14(7):686-94. DOI: 10.1038/modpathol.3880373. View

15.

Mills A, Zheng B, Wang X, Vogel H, Roop D, Bradley A . p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature. 1999; 398(6729):708-13. DOI: 10.1038/19531. View

16.

Brunner H, Hamel B, van Bokhoven H . The p63 gene in EEC and other syndromes. J Med Genet. 2002; 39(6):377-81. PMC: 1735150. DOI: 10.1136/jmg.39.6.377. View

17.

Chang C, Ye B, Chaganti R, Dalla-Favera R . BCL-6, a POZ/zinc-finger protein, is a sequence-specific transcriptional repressor. Proc Natl Acad Sci U S A. 1996; 93(14):6947-52. PMC: 38914. DOI: 10.1073/pnas.93.14.6947. View

18.

Macpartlin M, Zeng S, Lee H, Stauffer D, Jin Y, Thayer M . p300 regulates p63 transcriptional activity. J Biol Chem. 2005; 280(34):30604-10. DOI: 10.1074/jbc.M503352200. View

19.

Hall P, Campbell S, ONeill M, Royston D, Nylander K, Carey F . Expression of the p53 homologue p63alpha and deltaNp63alpha in normal and neoplastic cells. Carcinogenesis. 2000; 21(2):153-60. DOI: 10.1093/carcin/21.2.153. View

20.

Falini B, Fizzotti M, Pucciarini A, Bigerna B, Marafioti T, Gambacorta M . A monoclonal antibody (MUM1p) detects expression of the MUM1/IRF4 protein in a subset of germinal center B cells, plasma cells, and activated T cells. Blood. 2000; 95(6):2084-92. View